Figures & data
Table 1 Demographic features of the Romanian efficacy and safety subpopulations of the OSVaLD study
Figure 1 Changes from baseline in components of the DHI and in total DHI score in the Romanian efficacy population of the OSVaLD study.
Abbreviations: DHI, Dizziness Handicap Index; OSVaLD, Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms.
![Figure 1 Changes from baseline in components of the DHI and in total DHI score in the Romanian efficacy population of the OSVaLD study.](/cms/asset/88652ae9-b21d-488b-b6ad-edbb5c227f1d/dijg_a_71015_f0001_c.jpg)
Figure 2 Mean changes in elements of the DHI score in patients with diagnoses of Ménière’s disease, BPPV and PVVP. Total change (improvement) in DHI score is shown at the bottom of each column.
![Figure 2 Mean changes in elements of the DHI score in patients with diagnoses of Ménière’s disease, BPPV and PVVP. Total change (improvement) in DHI score is shown at the bottom of each column.](/cms/asset/daec5c70-6602-4cd9-935f-3d6c6f0fa419/dijg_a_71015_f0002_c.jpg)
Table 2 Trends in HADS-anxiety and HADS-depression scores and distributions in the Romanian efficacy population of the OSVaLD study
Figure 3 Changes from baseline in the domains of the SF-36v2 instrument in the Romanian efficacy population of the OSVaLD study (n=245).
Abbreviations: PF, physical functioning; RP, role limitation physical; BP, bodily pain; GH, general health perception; VT, vitality; SF, social functioning; RE, role limitation emotional; MH, mental health; OSVaLD, Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms; SD, standard deviation; SF-36v2, Medical Outcome Study Short-Form 36.
![Figure 3 Changes from baseline in the domains of the SF-36v2 instrument in the Romanian efficacy population of the OSVaLD study (n=245).](/cms/asset/dc25a7eb-9d42-4a51-8221-e903e3aafc55/dijg_a_71015_f0003_c.jpg)
Table 3 On-study trends in the PCS and MCS subscales of the SF-36v2 in the Romanian efficacy population of the OSVaLD study
Figure 4 Patients’ impression of betahistine therapy in the Romanian efficacy population of OSVaLD (n=245).
![Figure 4 Patients’ impression of betahistine therapy in the Romanian efficacy population of OSVaLD (n=245).](/cms/asset/76fbd35b-dc2f-42d3-b1c5-9678eb9b526d/dijg_a_71015_f0004_c.jpg)